Whitestar can deal with even the hardest nuclei

Article

Microincision cataract surgery (MICS) with the Whitestar ICE and CASE systems (AMO) can be performed safely and effectively even in the hardest nuclei, according to a Turkish study.

Microincision cataract surgery (MICS) with the Whitestar ICE and CASE systems (AMO) can be performed safely and effectively even in the hardest nuclei, according to a Turkish study.

Hasan Oguzhan and colleagues from the Dr Sadi Konuk Education and Research Hospital, Istanbul, Turkey performed MICS on 20 eyes (17 patients) using the Whitestar surgical system with ICE and CASE settings. Patients were selected according to their nucleus hardness (grade 3 – 4) and were examined for intraoperative complications, mean phaco time, total phaco %, effective phaco time (EPT), endothelial cell loss, postoperative corneal oedema and mean uncorrected and best corrected visual acuity.

The mean phaco time, total phaco % and EPT were one minute 24 seconds, 4.8% and 3.22 seconds, respectively. The mean preoperative and postoperative endothelial cell counts and percentage endothelial cell loss were 2 376, 2 253, and 5.2%, respectively. The mean early (within three days) postoperative uncorrected visual acuity and late postoperative best corrected visual acuity were 0.6 and 0.9 on the Snellen chart, respectively. There were no complications and surgery was performed safely in even the hardest nuclei.

It was the conclusion of the authors that bimanual MICS using the Whitestar ICE and CASE systems is both safe and effective even in the hardest nuclei.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.